Positive Basophil Tests Are Linked to High Disease Activity and Other Features of Autoimmune Chronic Spontaneous Urticaria: A Systematic Review.

Autoimmune chronic spontaneous urticaria Basophil activation test Basophil histamine release assay Biomarker Mast cell Treatment Type IIb aiCSU

Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
08 2023
Historique:
received: 06 02 2023
revised: 21 04 2023
accepted: 19 05 2023
medline: 11 8 2023
pubmed: 8 6 2023
entrez: 7 6 2023
Statut: ppublish

Résumé

Chronic spontaneous urticaria (CSU) is believed to be Autoimmune (aiCSU) (type IIb CSU) in at least 8% of patients, associated with mast cell-activating IgG autoantibodies. Basophil tests such as the basophil activation test (BAT) and basophil histamine release assay (BHRA) are considered the best single tests for an aiCSU diagnosis. To date, the strength of associations among a positive BAT and/or BHRA (BAT/BHRA To evaluate the strength of current evidence on basophil tests as parameters for CSU characteristics. We performed a systematic literature search and review to assess the relationship between BAT/BHRA In CSU patients, BAT/BHRA Our results suggest that aiCSU defined by BAT/BHRA

Sections du résumé

BACKGROUND
Chronic spontaneous urticaria (CSU) is believed to be Autoimmune (aiCSU) (type IIb CSU) in at least 8% of patients, associated with mast cell-activating IgG autoantibodies. Basophil tests such as the basophil activation test (BAT) and basophil histamine release assay (BHRA) are considered the best single tests for an aiCSU diagnosis. To date, the strength of associations among a positive BAT and/or BHRA (BAT/BHRA
OBJECTIVE
To evaluate the strength of current evidence on basophil tests as parameters for CSU characteristics.
METHODS
We performed a systematic literature search and review to assess the relationship between BAT/BHRA
RESULTS
In CSU patients, BAT/BHRA
CONCLUSIONS
Our results suggest that aiCSU defined by BAT/BHRA

Identifiants

pubmed: 37286132
pii: S2213-2198(23)00603-7
doi: 10.1016/j.jaip.2023.05.039
pii:
doi:

Substances chimiques

Immunoglobulin E 37341-29-0

Types de publication

Systematic Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2411-2416

Informations de copyright

Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Auteurs

Sherezade Moñino-Romero (S)

Allergology and Immunology Department, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Yana Hackler (Y)

Allergology and Immunology Department, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Tiia-Linda Okas (TL)

Department of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.

Eva Maria Grekowitz (EM)

Allergology and Immunology Department, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Joachim W Fluhr (JW)

Allergology and Immunology Department, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Vincent Hultsch (V)

Allergology and Immunology Department, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Lea Alice Kiefer (LA)

Allergology and Immunology Department, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Polina Pyatilova (P)

Allergology and Immunology Department, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Dorothea Terhorst-Molawi (D)

Allergology and Immunology Department, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Yi-Kui Xiang (YK)

Allergology and Immunology Department, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Frank Siebenhaar (F)

Allergology and Immunology Department, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Marcus Maurer (M)

Allergology and Immunology Department, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Pavel Kolkhir (P)

Allergology and Immunology Department, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. Electronic address: pavel.kolkhir@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH